June 2019 - Volume 3 - Issue S1 - Contributor Index

PB1669 RISK FACTORS FOR THROMBOEMBOLISM IN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA

Boban, A.; Mikulic, M.; Serventi-Seiwerth, R.; More

HemaSphere. 3(S1):771, June 2019.

PB2175 LONG TERM FOLLOW-UP OF MAINTENANCE THERAPY WITH INTEREFRON ALPHA AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT IN MULTIPLE MYELOMA PATIENTS–SINGLE CENTER EXPERIENCE

Batinic, J.; Bašic-Kinda, S.; Pulanic, D.; More

HemaSphere. 3(S1):976, June 2019.

PB2327 SUBSTITUTING CARMUSTINE WITH BENDAMUSTINE IN BEAM RESULTS IN DELAYED PLATELET RECOVERY AND LESS MUCOSITIS WITH SIMILAR EFFICACY – A MATCHED PAIR ANALYSIS

Aurer, I.; Zekanovic, I.; Durakovic, N.; More

HemaSphere. 3(S1):1037, June 2019.

Author:
Babaeva, F.
Author:
Babaoglu, K.
Author:
Babenko, E.

PS960 BLINATUMOMAB - BASED THERAPIES IN CHILDREN AND ADULTS WITH MRD+ AND R/R B-ALL, EXPERIENCE FROM A SINGLE CENTER (CIC 725)

Markova, I.; Bondarenko, S.; Bondarenko, S.; More

HemaSphere. 3(S1):432, June 2019.

PS960 BLINATUMOMAB - BASED THERAPIES IN CHILDREN AND ADULTS WITH MRD+ AND R/R B-ALL, EXPERIENCE FROM A SINGLE CENTER (CIC 725)

Markova, I.; Bondarenko, S.; Bondarenko, S.; More

HemaSphere. 3(S1):432, June 2019.

Author:
Babiker, H.

PB1737 MULTICENTER, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE BIOEQUIVALENCE AND FOOD EFFECT ON THE BIOAVAILABILITY OF CC-486 (ORAL AZACITIDINE) TABLETS IN ADULT CANCER PATIENTS

Babiker, H.; Milhem, M.; Aisner, J.; More

HemaSphere. 3(S1):799, June 2019.

Author:
Babon, J.J.
Author:
BABU, G.
Author:
Baccarani, M.

S123 SETD2 LOSS OF FUNCTION IS A RECURRENT EVENT IN ADVANCED-PHASE CHRONIC MYELOID LEUKEMIA INDUCED BY POST-TRANSLATIONAL MECHANISMS THAT CAN BE THERAPEUTICALLY TARGETED

Mancini, M.; De Santis, S.; Monaldi, C.; More

HemaSphere. 3(S1):13-14, June 2019.

S882 OPTIMIZATION OF TKI TREATMENT IN ELDERLY PATIENTS WITH PH+ CHRONIC MYELOID LEUKEMIA AND STABLE MR3.0 OR MR4.0: 1ST YEAR RESULTS OF THE ITALIAN MULTICENTRIC PHASE-III RANDOMIZED OPTKIMA STUDY

Malagola, M.; Efficace, F.; Polverelli, N.; More

HemaSphere. 3(S1):396-397, June 2019.

Author:
Baccini, V.
Author:
Bacher, V. U.
Author:
Bachier, C.R.

PS1533 KD025–208: A PHASE 2A TRIAL OF KD025 FOR PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) – UPDATED SAFETY AND EFFICACY

Salhotra, A.; Zoghi, B.; Essell, J.; More

HemaSphere. 3(S1):707-708, June 2019.

Author:
Bachy, E.

PS1303 CHRONIC TCR STIMULATION PROMOTES PERIPHERAL T-CELL LYMPHOMAGENESIS AND INDUCES ADDICTION TO SYK AND NK RECEPTOR SIGNALING

Carras, S.; Chartoire, D.; Marcais, A.; More

HemaSphere. 3(S1):595, June 2019.

S1600 REAL-WORLD RESULTS ON CD19 CAR T-CELL FOR 60 FRENCH PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA INCLUDED IN A TEMPORARY AUTHORIZATION FOR USE (ATU) PROGRAM

Thieblemont, C.; Legouill, S.; Di Blasi, R.; More

HemaSphere. 3(S1):736-737, June 2019.

Author:
Bacigalupo, A.

PF759 ALLOGENEIC STEM CELL TRANSPLANTATION FOR HEMATOLOGICAL MALIGNANCIES FROM HLA IDENTICAL SIBLINGS OR HAPLOIDENTICAL DONORS: A COMPARISON

Corbingi, A.; Dragonetti, G.; Galli, E.; More

HemaSphere. 3(S1):333-334, June 2019.

S1624 A DAY 100 LAB-SCORE PREDICTS EXTENSIVE CGVHD, OVERALL SURVIVAL AND TRANSPLANT-RELATED MORTALITY AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: FINAL ANALYSIS

Metafuni, E.; Cavattoni, I.; Lamparellli, T.; More

HemaSphere. 3(S1):750, June 2019.

PB2161 TREATMENT OF PRIMARY PLASMA CELL LEUKEMIA WITH HIGH DOSES OF CYCLOPHOPHAMIDE, BORTEZOMIB AND DEXAMETHASONE FOLLOWED BY DOUBLE AUTOLOGOUS HSCT

Pagano, L.; Maraglino, A. E. M.; Criscuolo, M.; More

HemaSphere. 3(S1):971, June 2019.

Author:
Backs, J.
Author:
Baclig, N.V.

PF253 SAFETY AND RESOURCE UTILIZATION FOLLOWING EARLY HOSPITAL DISCHARGE AFTER INDUCTION CHEMOTHERAPY FOR ACUTE MYELOID LEUKEMIA (AML): A 4-YEAR RETROSPECTIVE ANALYSIS

Howard, N.P.; Halpern, A.B.; Othus, M.; More

HemaSphere. 3(S1):78, June 2019.

Author:
Bacon, P.

PS1003 HARMONY ALLIANCE: EUROPEAN PUBLIC-PRIVATE DATA COLLECTION LEADS THE WAY - FIRST RESULTS OF THE “PROOF-OF-PRINCIPLE” STUDY IN ACUTE MYELOID LEUKEMIA

Bullinger, L.; Valk, P.; Versluis, J.; More

HemaSphere. 3(S1):451, June 2019.

PS1418 POMALIDOMIDE-BASED TREATMENT IN RELAPSED REFRACTORY MULTIPLE MYELOMA: ANALYSIS OF BASELINE CHARACTERISTICS AND SAFETY PROFILE OF PATIENTS WHO DIED IN THE EUROPEAN POST APPROVAL SAFETY STUDY

Gamberi, B.; Abildgaard, N.; Payer, A. Ramirez; More

HemaSphere. 3(S1):652, June 2019.

PS1420 RESULTS FROM A POST-AUTHORIZATION SAFETY STUDY COMPARING LENALIDOMIDE-BASED WITH NON–LENALIDOMIDE-BASED TREATMENT IN TRANSPLANT-INELIGIBILE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS

De Stefano, V.; Cavo, M.; Payer, A. Ramirez; More

HemaSphere. 3(S1):653-654, June 2019.

PB2117 POMALIDOMIDE PLUS LOW-DEXAMETHASONE TREATMENT FOR ≥ 1 YEAR IN PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA AND RENAL IMPAIRMENT: A SUBANALYSIS OF THE MM-013 PHASE 2 STUDY

Weisel, K.; Dimopoulos, M.; Cook, M.; More

HemaSphere. 3(S1):953, June 2019.

Author:
Bacovsky, J.
Author:
Baculea, S.
Author:
badarkhe, G.
Author:
Badazhapova, D.
Author:
Badell, I.
Author:
Badens, C.
Author:
Bader, P.

S1618 TISAGENLECLEUCEL APPEARS EFFECTIVE AND SAFE IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA WITH HIGH-RISK CYTOGENETIC ABNORMALITIES

Grupp, S.; Maude, S.; Baruchel, A.; More

HemaSphere. 3(S1):746-747, June 2019.

Author:
Badiali, L.

PF338 DEVELOPMENT AND OPTIMISATION OF A FULLY HUMAN FVIII MIMETIC BISPECIFIC ANTIBODY FOR PATIENTS WITH HAEMOPHILIA A

Wang, W.; Blackwood, J.; Magliozzi, R.; More

HemaSphere. 3(S1):120-121, June 2019.

Author:
Badiola, J.

PB1898 SAFETY AND EFFECTIVENESS OF CHLORAMBUCIL-OBINUTUZUMAB IN THE FRONT LINE TREATMENT OF UNFIT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: REAL-LIFE DATA FROM ANDALUSIAN LYMPHOID NEOPLASM GROUP (GRANEL)

Puerta Puerta, J.M.; Martín Palanco, V.; Badiola, J.; More

HemaSphere. 3(S1):865, June 2019.

PB2267 PERCEPTION OF THE DISCONTINUATION OF TYROSINE-KINASE INHIBITOR TREATMENT IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA OF THE ANDALUSIAN GROUP OF CML (GALMC)

Fernandez, E. L.ó.pez; Puerta, J. M. Puerta; Badiola, J.; More

HemaSphere. 3(S1):1013-1014, June 2019.

Author:
Badman, J.
Author:
Baech, J.

PF304 OSTEOPOROSIS AND LOW-ENERGY FRACTURES AFTER TREATMENT FOR LYMPHOMA WITH CORTICOSTEROID-CONTAINING IMMUNOCHEMOTHERAPY: A DANISH NATIONWIDE COHORT STUDY

Baech, J.; Hansen, S.M.; Øvlisen, A.K.; More

HemaSphere. 3(S1):104, June 2019.

Author:
Baek, D.W.
Author:
Baek, H. J.
Author:
Baer, C.

PF532 INTEGRATED PROFILING OF DNA METHYLATION AND MUTATIONS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES

Morimoto, S.; Makishima, H.; Nagata, Y.; More

HemaSphere. 3(S1):218-219, June 2019.

Author:
Baer, M.

PF251 GILTERITINIB PROLONGS SURVIVAL IN PATIENTS WITH FLT3-MUTATED RELAPSED/REFRACTORY AML WHO HAVE COMMON AML CO-MUTATIONS OR A HIGH FLT3-ITD ALLELIC RATIO

Levis, M.; Perl, A.; Martinelli, G.; More

HemaSphere. 3(S1):77, June 2019.

PF269 FT-2102, AN IDH1 M INHIBITOR, COMBINED WITH AZACITIDINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS): RESULTS FROM A PHASE 1 STUDY

Cortes, J.E.; Watts, J.; Baer, M.; More

HemaSphere. 3(S1):86-87, June 2019.

S876 GILTERITINIB SIGNIFICANTLY PROLONGS OVERALL SURVIVAL IN PATIENTS WITH FLT3-MUTATED (FLT3MUT+) RELAPSED/REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML): RESULTS FROM THE PHASE 3 ADMIRAL TRIAL

Perl, A.; Martinelli, G.; Cortes, J.; More

HemaSphere. 3(S1):392-393, June 2019.

PS1024 IMPACT OF MINIMAL RESIDUAL DISEASE AND COMPLETE REMISSION (CR)/CR WITH PARTIAL HEMATOLOGIC RECOVERY ON SURVIVAL AFTER GILTERITINIB THERAPY IN PATIENTS WITH FLT3-MUTATED RELAPSED/REFRACTORY AML

Levis, M.; Perl, A.; Altman, J.; More

HemaSphere. 3(S1):461, June 2019.

PS1051 FT-2102, AN IDH1 M INHIBITOR, INDUCES MUTATION CLEARANCE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS) TREATED IN PHASE 1 DOSE ESCALATION AND EXPANSION STUDY

Botton, S. De; Watts, J.; Baer, M.; More

HemaSphere. 3(S1):475-476, June 2019.

Author:
Baer, M.R.

PS945 KTE-X19, AN ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY, IN ADULT PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA: END OF PHASE 1 RESULTS OF ZUMA-3

Shah, B.D.; Bishop, M.R.; Oluwole, O.O.; More

HemaSphere. 3(S1):426, June 2019.

PF442 TREATMENT WITH 5-AZACYTIDINE RESULTS IN EXPRESSION OF LONG TERMINAL REPEAT (LTR) ELEMENTS IN PERIPHERAL BLOOD MONONUCLEAR CELLS OF PATIENTS WITH MDS AND AML: FIRST PILOT STUDY

Daskalakis, M.; Haubitz, M.; Steiner, D.; More

HemaSphere. 3(S1):174, June 2019.

Author:
Baffert, S.
Author:
Bagger, F.O.

PF449 INACTIVATION OF THE NUCLEAR INTERACTING SET DOMAIN PROTEIN 1 IMPAIRS GATA1-REGULATED TERMINAL ERYTHROID MATURATION AND INDUCES ERYTHROLEUKEMIA

Almosailleakh, M.; Tauchmann, S.; Leonards, K.; More

HemaSphere. 3(S1):176-177, June 2019.

Author:
Bagguley, T.

S838 TRANSFUSION DEPENDENCY IS ASSOCIATED WITH PRESENCE OF TOXIC IRON SPECIES AND INFERIOR SURVIVAL IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES

Hoeks, M.; Bagguley, T.; Roelofs, R.; More

HemaSphere. 3(S1):373, June 2019.

Author:
Bagnoli, J.W.
Author:
Bagot, C.

PF691 SPLENECTOMY IN IMMUNE THROMBOCYTOPENIA: DO CHANGING TREATMENT PATTERNS FOR ITP AFFECT OUTCOMES? DATA FROM THE UK ITP REGISTRY

Todd, S.; Infirri, S. Sardo; Miah, H.; More

HemaSphere. 3(S1):299-300, June 2019.

Author:
Bagot, M.

PS1256 CONTEMPORARY TREATMENT PATTERNS AND RESPONSE IN RELAPSE/REFRACTORY CUTANEOUS T-CELL LYMPHOMA (CTCL) IN CLINICAL PRACTICE IN FRANCE, GERMANY ITALY, SPAIN AND THE UNITED KINGDOM

Illidge, T.; Bagot, M.; Waser, N.; More

HemaSphere. 3(S1):573-574, June 2019.

Author:
Bahadir, A.
Author:
Bahceci, E.

PF251 GILTERITINIB PROLONGS SURVIVAL IN PATIENTS WITH FLT3-MUTATED RELAPSED/REFRACTORY AML WHO HAVE COMMON AML CO-MUTATIONS OR A HIGH FLT3-ITD ALLELIC RATIO

Levis, M.; Perl, A.; Martinelli, G.; More

HemaSphere. 3(S1):77, June 2019.

S876 GILTERITINIB SIGNIFICANTLY PROLONGS OVERALL SURVIVAL IN PATIENTS WITH FLT3-MUTATED (FLT3MUT+) RELAPSED/REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML): RESULTS FROM THE PHASE 3 ADMIRAL TRIAL

Perl, A.; Martinelli, G.; Cortes, J.; More

HemaSphere. 3(S1):392-393, June 2019.

PS1024 IMPACT OF MINIMAL RESIDUAL DISEASE AND COMPLETE REMISSION (CR)/CR WITH PARTIAL HEMATOLOGIC RECOVERY ON SURVIVAL AFTER GILTERITINIB THERAPY IN PATIENTS WITH FLT3-MUTATED RELAPSED/REFRACTORY AML

Levis, M.; Perl, A.; Altman, J.; More

HemaSphere. 3(S1):461, June 2019.

PS1065 OPEN-LABEL STUDY OF GILTERITINIB, GILTERITINIB PLUS AZACITIDINE, OR AZACITIDINE ALONE IN NEWLY DIAGNOSED FLT3-MUTATED AML PATIENTS INELIGIBLE FOR INTENSIVE CHEMOTHERAPY: RESULTS FROM THE SAFETY COHORT

Esteve, J.; Schots, R.; Del Castillo, T. Bernal; More

HemaSphere. 3(S1):482, June 2019.

Author:
Bahlis, N.

PF587 SELINEXOR, POMALIDOMIDE, AND DEXAMETHASONE (SPD) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

Chen, C.; Gasparetto, C.; White, D.; More

HemaSphere. 3(S1):245, June 2019.

PF592 IMPACT OF AGE ON EFFICACY AND SAFETY OF DARATUMUMAB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE (D-RD) IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): MAIA

Hulin, C.; Facon, T.; Kumar, S.; More

HemaSphere. 3(S1):248-249, June 2019.

S823 RANDOMIZED, OPEN-LABEL, NON-INFERIORITY, PHASE 3 STUDY OF SUBCUTANEOUS (SC) VERSUS INTRAVENOUS (IV) DARATUMUMAB (DARA) ADMINISTRATION IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: COLUMBA

Mateos, M.-V.; Nahi, H.; Legiec, W.; More

HemaSphere. 3(S1):364, June 2019.

PS1414 A PHASE 1B/2 STUDY OF SELINEXOR, CARFILZOMIB, AND DEXAMETHASONE (SKD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

Gasparetto, C.; Lentzsch, S.; Schiller, G.; More

HemaSphere. 3(S1):650, June 2019.

S1606 SAFETY AND EFFICACY OF COMBINATION OF SELINEXOR, DARATUMUMAB, AND DEXAMETHASONE (SDD) IN PATIENTS WITH MULTIPLE MYELOMA (MM) PREVIOUSLY EXPOSED TO PROTEASOME INHIBITORS AND IMMUNOMODULATORY DRUGS

Gasparetto, C.; Lentzsch, S.; Schiller, G.; More

HemaSphere. 3(S1):740, June 2019.

PB2137 SUBGROUP ANALYSIS OF PATIENTS FROM CANADA AND THE UNITED STATES IN THE PHASE 3 FIRST TRIAL IN TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA

Belch, A.; Bahlis, N.; White, D.; More

HemaSphere. 3(S1):962, June 2019.

Author:
Bahlis, N.J.

PF591 EFFICACY AND SAFETY OF DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE (D-RD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED SUBGROUP ANALYSIS OF POLLUX BASED ON CYTOGENETIC RISK

Dimopoulos, M.A.; San-Miguel, J.; White, D.; More

HemaSphere. 3(S1):247-248, June 2019.

PF603 FASTER & SUSTAINED IMPROVEMENT IN HEALTH-RELATED QUALITY OF LIFE IN TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PTS TREATED WITH DARATUMUMAB, LENALIDOMIDE & DEXAMETHASONE (D-RD) VS RD: MAIA

Perrot, A.; Facon, T.; Plesner, T.; More

HemaSphere. 3(S1):255, June 2019.

PF631 HEALTH-RELATED QUALITY OF LIFE WITH POMALIDOMIDE + LOW-DOSE DEXAMETHASONE + DARATUMUMAB IN PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA AFTER LENALIDOMIDE TREATMENT

Reece, D.; Bahlis, N.J.; Samaras, C.; More

HemaSphere. 3(S1):268-269, June 2019.

Author:
Bahlo, J.

S105 GENETIC MARKERS AND OUTCOME IN THE CLL14 TRIAL OF THE GCLLSG COMPARING FRONT LINE OBINUTUZUMAB PLUS CHLORAMBUCIL OR VENETOCLAX IN PATIENTS WITH COMORBIDITY

Tausch, E.; Bahlo, J.; Robrecht, S.; More

HemaSphere. 3(S1):4, June 2019.

S106 HIGH EFFICACY OF VENETOCLAX PLUS OBINUTUZUMAB IN PATIENTS WITH COMPLEX KARYOTYPE (CKT) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A PROSPECTIVE ANALYSIS FROM THE CLL14 TRIAL

Al-Sawaf, O.; Lilienweiss, E.; Bahlo, J.; More

HemaSphere. 3(S1):4-5, June 2019.

S149 FIXED-DURATION VENETOCLAX PLUS OBINUTUZUMAB IMPROVES PROGRESSION-FREE SURVIVAL AND MINIMAL RESIDUAL DISEASE NEGATIVITY IN PATIENTS WITH PREVIOUSLY UNTREATED CLL AND COMORBIDITIES

Fischer, K.; Al-Sawaf, O.; Bahlo, J.; More

HemaSphere. 3(S1):26-27, June 2019.